Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy

• DOI: 10.1186/s12967-018-1679-0
• Publication Date: 2018-11-09T13:35:30Z
• Authors: Wataru Goto; Shinichiro Kashiwagi; Koji Takada; Yuka Asano; Katsuyuki Takahashi; Hisakazu Fujita; Tsutomu Takashima; Shuhei Tomita; Kosei Hirakawa; Masaichi Ohira
• Keywords: Triple-negative breast cancer; Progesterone receptor

The prognosis of breast cancer and the treatment response to neoadjuvant chemotherapy (NAC) differ depending on intrinsic molecular subtypes. We evaluated prognostic significance immunohistological subtypes in patients with recurrent after NAC surgery.A total 237 treated subsequent curative surgery between 2007 2015 were analyzed. correlation clinicopathological features, prognosis, pathological complete (pCR) rate investigated retrospectively.There 55 (23.2%) recurrence surgery. No significant difference post-recurrence survival (PRS) was noted among (p = 0.397). In estrogen receptor-positive human epidermal growth factor receptor (HER) 2-negative (luminal) malignancy, PRS significantly better pCR group than non-pCR 0.031). Conversely, not a predictor improved triple-negative (TNBC; p 0.329). Multivariate analysis revealed that efficacy [hazard ratio (HR) 300.204, < 0.001] initial metastasis site (HR 15.037, 0.005) independent predictors for luminal cancer, while Ki-67 51.171, 0.020) 13.318, 0.048) TNBC.The factors each subtype should be separately following